Sector News

Sanofi parts ways with Oxford BioMedica on hemophilia tie-up inked by Bioverativ

March 20, 2021
Life sciences

Just a few weeks after Sanofi agreed to purchase Bioverativ to gain a foothold in hemophilia, the smaller company struck a licensing deal with Oxford BioMedica to develop and manufacture lentiviral vectors for the disease.

That deal is no more. After ending a previous development deal with the U.K.-based company last year—and as its own phase 3 program in hemophilia moves forward—Sanofi is pulling out of its remaining Oxford BioMedica collaboration.

Oxford BioMedica on Friday said Sanofi had decided to terminate the viral vector deal, first struck in February 2018. Under the original pact, potentially worth more than $100 million, Oxford BioMedica licensed its LentiVector Enabled tech to Bioverativ and allowed its partner access to its manufacturing know-how.

Sanofi had inked its Bioverativ buyout the prior month—in January 2018—and the buyout closed in March 2018. Bioverativ is a 2017 spinoff from Biogen.

Meanwhile, Sanofi has its own promising hemophilia A and B candidate in fitusiran. The company says the late-stage drug candidate has the “potential to transform the treatment of hemophilia.” The drug scored an FDA fast track designation last month.

Aside from the hemophilia collaboration it’s ending, Sanofi more than a decade ago licensed two gene therapy candidates from Oxford BioMedica. Without plans to move forward on those programs, the pharma company last year returned them to their original owner.

Under CEO Paul Hudson’s new “play to win” strategy, Sanofi is prioritizing development on pipeline candidates with the potential to change medical practice. The company has identified meds in cancer, hemophilia and multiple sclerosis, among other diseases, that fit the description, the CEO has said.

Aside from Oxford BioMedica’s work in gene therapy and hemophilia, the company has also jumped into the COVID-19 response. The company has partnered to scale up vaccine production with AstraZeneca as that drugmaker works to deliver on its goal to deliver billions of doses.

by Eric Sagonowsky

Source: fiercepharma.com

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).